Terms: = Ovarian cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
19 results:
1. Circulating Tumor Cells Characterization Revealed timp1 as a Potential Therapeutic Target in ovarian cancer.
Abreu M; Cabezas-Sainz P; Alonso-Alconada L; Ferreirós A; Mondelo-Macía P; Lago-Lestón RM; Abalo A; Díaz E; Palacios-Zambrano S; Rojo-Sebastian A; López-López R; Sánchez L; Moreno-Bueno G; Muinelo-Romay L
Cells; 2020 May; 9(5):. PubMed ID: 32423054
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Candidate Genes Associated with Chemotherapy Resistance in ovarian cancer.
Zhang B; Wang L; Zhao X; Wei Y; Zhang Y
Ann Clin Lab Sci; 2018 Sep; 48(5):573-579. PubMed ID: 30373860
[TBL] [Abstract] [Full Text] [Related]
3. New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.
Bukowska B; Rogalska A; Marczak A
Life Sci; 2016 Apr; 151():86-92. PubMed ID: 26944437
[TBL] [Abstract] [Full Text] [Related]
4. Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Jiang WG; Sanders AJ; Katoh M; Ungefroren H; Gieseler F; Prince M; Thompson SK; Zollo M; Spano D; Dhawan P; Sliva D; Subbarayan PR; Sarkar M; Honoki K; Fujii H; Georgakilas AG; Amedei A; Niccolai E; Amin A; Ashraf SS; Ye L; Helferich WG; Yang X; Boosani CS; Guha G; Ciriolo MR; Aquilano K; Chen S; Azmi AS; Keith WN; Bilsland A; Bhakta D; Halicka D; Nowsheen S; Pantano F; Santini D
Semin Cancer Biol; 2015 Dec; 35 Suppl():S244-S275. PubMed ID: 25865774
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of timp-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.
Desmeules P; Trudel D; Turcotte S; Sirois J; Plante M; Grégoire J; Renaud MC; Orain M; Têtu B; Bairati I
Hum Pathol; 2015 May; 46(5):739-45. PubMed ID: 25771900
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
[TBL] [Abstract] [Full Text] [Related]
7. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract] [Full Text] [Related]
8. Enhanced immunoreactivity of timp-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.
Hałoń A; Nowak-Markwitz E; Donizy P; Matkowski R; Maciejczyk A; Gansukh T; Györffy B; Spaczyński M; Zabel M; Lage H; Surowiak P
J Histochem Cytochem; 2012 Jul; 60(7):491-501. PubMed ID: 22511598
[TBL] [Abstract] [Full Text] [Related]
9. Expression of MMP-2, -7, -9, MT1-MMP and timp-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract] [Full Text] [Related]
10. Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers.
van Haaften C; Duke CC; Weerheim AM; Smit NP; van Haard PM; Darroudi F; Trimbos BJ
J Exp Clin Cancer Res; 2011 Mar; 30(1):29. PubMed ID: 21401934
[TBL] [Abstract] [Full Text] [Related]
11. Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells.
Yan L; Lin B; Gao L; Gao S; Liu C; Wang C; Wang Y; Zhang S; Iwamori M
Int J Mol Sci; 2010 Nov; 11(11):4441-52. PubMed ID: 21151448
[TBL] [Abstract] [Full Text] [Related]
12. Lack of relationship between timp-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Christensen RK; Bartels A; Brünner N; Jakobsen A
BMC Cancer; 2010 May; 10():185. PubMed ID: 20459644
[TBL] [Abstract] [Full Text] [Related]
13. timp-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S; Woelber L; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mueller V
BMC Cancer; 2010 Apr; 10():139. PubMed ID: 20388222
[TBL] [Abstract] [Full Text] [Related]
14. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
Stettner R; Bogusiewicz M; Rechberger T
Ginekol Pol; 2009 Jan; 80(1):47-53. PubMed ID: 19323060
[TBL] [Abstract] [Full Text] [Related]
15. Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.
Obayashi Y; Yabushita H; Kanyama K; Noguchi M; Zhuo L; Kimata K; Wakatsuki A
Oncol Rep; 2008 May; 19(5):1245-51. PubMed ID: 18425383
[TBL] [Abstract] [Full Text] [Related]
16. Gelatinases and their tissue inhibitors in ovarian tumors; timp-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract] [Full Text] [Related]
17. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract] [Full Text] [Related]
19. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer.
Stadlmann S; Pollheimer J; Moser PL; Raggi A; Amberger A; Margreiter R; Offner FA; Mikuz G; Dirnhofer S; Moch H
Eur J Cancer; 2003 Nov; 39(17):2499-505. PubMed ID: 14602136
[TBL] [Abstract] [Full Text] [Related]
